共 60 条
[1]
Heimbach JK(2018)AASLD guidelines for the treatment of hepatocellular carcinoma Hepatology. 67 358-80
[2]
Kulik LM(2018)Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases Hepatology. 68 723-50
[3]
Finn RS(2018)Cabozantinib in patients with advanced and progressing hepatocellular carcinoma N Engl J Med 379 54-63
[4]
Sirlin CB(2015)Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade J Clin Oncol 33 550-8
[5]
Abecassis MM(2017)Albumin-bilirubin grade predicts prognosis of HCC patients with sorafenib use J Gastroenterol Hepatol 32 1975-81
[6]
Roberts LR(2011)Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 2298-308
[7]
Marrero JA(2020)SO-9 Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo Ann Oncol 31 S220-28
[8]
Kulik LM(2016)A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma Liver Int 36 1821-15
[9]
Sirlin CB(2017)Albumin-Bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications Liver Cancer 6 204-43
[10]
Zhu AX(2020)EZ-ALBI score for predicting hepatocellular carcinoma prognosis Liver Cancer 9 734-undefined